Advertisement
News
Subscribe to MDT Magazine News

New NeuroPhage funding to back move to Alzheimer's trial

March 2, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

NeuroPhage Pharmaceuticals Inc., which closed a $12.4M Series B round Tuesday, said that it plans to use the funds to get its lead compound to treat Alzheimer's disease, NPT001, into a Phase 1 clinical trial in about a year and a half.

$3.6 million research project underway to reduce mother and baby deaths in Malawi

March 2, 2011 8:37 am | by EurekAlert | Comments

(University of Warwick) Warwick Medical School has just begun a ?2.6 ($3.6) million three year research and training program to train Malawian clinical officers in a bid to reduce the country's high death rate for pregnant mothers and babies.

TOPICS:

Accretive Health 4th-quarter profit surges

March 2, 2011 7:45 am | by The Associated Press | Comments

Accretive Health Inc., which helps hospital systems manage their revenue cycles, said Wednesday its fourth-quarter profit more than doubled on higher services revenue.Accretive said its net income rose to $5.5 million, or 6 cents per share, up from $2.3 million, or 5 cents per share, during the...

Advertisement

FDA CONSUMER HEALTH INFORMATION - FDA Intends to Remove Unapproved Drugs From Market

March 2, 2011 7:35 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., March 2, 2011 /PRNewswire-USNewswire/ -- Do you use a prescription cough, cold, or allergy relief drug? (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Federal regulators aim to take certain unapproved prescription medicines intended to relieve cough, cold,...

TOPICS:

FDA Prompts Removal of Unapproved Drugs From Market

March 2, 2011 6:39 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., March 2, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today took action against companies that manufacture, distribute, or market certain unapproved prescription oral cough, cold, and allergy products. The affected products cannot be legally...

TOPICS:

Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government

March 2, 2011 6:36 am | by Bio-Medicine.Org | Comments

EAST SETAUKET, N.Y., March 2, 2011 /- Lixte Biotechnology Holdings (OTC: LIXT) announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project (QTDP).  This grant was awarded to further development and commercialization of Lixte's...

TOPICS:

Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference

March 2, 2011 6:35 am | by Bio-Medicine.Org | Comments

CLINTON, N.J., March 2, 2011 /- Ikaria, Inc. today announced that its Chairman and CEO, Daniel Tasse, will present at the 31st Annual Cowen and Company Healthcare Conference on Wednesday, March 9, 2011 at 8:30 a.m. EST.  The conference will be held March 7-9 at the Boston Marriott...

TOPICS:

Unapproved Cough, Cold, Allergy Products: FDA Prompts Removal From Market

March 2, 2011 6:30 am | by U.S. Food & Drug Administration | Comments

Unapproved products have not been evaluated by the FDA for safety, effectiveness, and quality.

TOPICS:
Advertisement

Proton Pump Inhibitor drugs (PPIs): Drug Safety Communication - Low Magnesium Levels Can Be Associated With Long-Term Use

March 2, 2011 5:30 am | by U.S. Food & Drug Administration | Comments

Prolonged treatment with prescription PPIs may lead to low serum magnesium levels, which can result in serious adverse events including muscle spasm (tetany), irregular heartbeat (arrhythmias), and convulsions (seizures).

TOPICS:

e-MDs Continues Track Record of Employee and Revenue Growth

March 2, 2011 4:36 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, March 2, 2011 /- e-MDs, a leading provider of electronic health records (EHRs), is proud to announce another year of record revenue and employee growth.  In 2010 e-MDs doubled their growth rate from the previous two years.  Total employee count grew from 209 to...

TOPICS:

Naviscan Announces European Launch of Positron Emission Mammography

March 2, 2011 4:35 am | by Bio-Medicine.Org | Comments

VIENNA, March 2, 2011 /- Naviscan, Inc., announces the European launch of the Naviscan Positron Emission Mammography (PEM) scanner at two prestigious radiology conferences in Vienna.  On March 3rd, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, a podium...

TOPICS:

PositiveID Corporation Reaches Important Chemistry Milestone in Development of Its GlucoChip(TM) Glucose-Sensing Microchip

March 2, 2011 4:33 am | by PositiveID | Comments

PositiveID Corporation Reaches Important Chemistry Milestone in Development of Its GlucoChip(TM) Glucose-Sensing Microchip

TOPICS:

Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.

March 2, 2011 4:32 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 2, 2011 /- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed an...

TOPICS:

Myriad board approves $100 million buyback plan

March 2, 2011 3:45 am | by The Associated Press | Comments

Myriad Genetics Inc. said Wednesday its board of directors approved a $100 million stock buyback program.The company said it will repurchase $50 million in stock from J.P. Morgan as part of the new program.The remaining $50 million will be repurchased through open market or privately negotiated...

Nile Therapeutics Receives Positive NASDAQ Panel Decision

March 2, 2011 3:35 am | by Bio-Medicine.Org | Comments

SAN MATEO, Calif., March 2, 2011 /- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced that, on March 1, 2011, the Company received a positive determination from the NASDAQ Listing Qualifications...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading